The optimization of helper T lymphocyte (HTL) function in vaccine development

Immunologic Research

Volumn 18, Issue 2, 1998, Pages 79-92

  Alexander, Jeff ^a   Fikes, John ^a   Hoffman, Stephen ^b   Franke, Eileen ^b   Sacci, John ^b   Appella, Ettore ^c   Chisari, Francis V ^d   Guidotti, Luca G ^d   Chesnut, Robert W ^a   Livingston, Brian ^a   Sette, Alessandro ^a,e  

^a Epimmune   (United States)

^b Naval Research Medical Institute   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e NONE   (United States)

Author keywords

HBV; Malaria; PAN DR T cell helper epitiopes (PADRE); Peptide based vaccines

Indexed keywords

ANTIBODY; ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; PEPTIDE;

ANTIBODY RESPONSE; B LYMPHOCYTE; BINDING AFFINITY; CELLULAR IMMUNITY; CROSS REACTION; DRUG POTENCY; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SPOROZOITE; VACCINE PRODUCTION; VIRUS INFECTION;

EID: 7844235804     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02788751     Document Type: Review

References (145)

1. Fitch FW, Lancki DW, Gajewski TF: T-cell-mediated immune regulation: help, suppression In: Fundamental Immunology, Paul WE (ed): Raven, New York,: 1993, 773.
2. Mosmann TR, Sad S: 1996 The expanding universe of T-cell subsets: Th1, Th2, more. Immunol Today 17:138.
3. Abbas AK, Murphy KM, Sher A: 1996 Functional diversity of helper T lymphocytes. Nature 383:787.
4. Reiner SL, Locksley RM: 1995 The regulation of immunity to Leishmania major. Ann Rev Immunol 13:151.
5. Topalian SL: 1994 MHC class II restricted tumor antigens, the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol 6:741.
6. Clerici M, Giori JV, Chou C-C, Gudeman VK, Zack JA, et al.: 1992 Cell mediated immune response to human immunodeficiency virus type I (HIV-1) in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 165:1012.
7. Clerici M, Shearer GM: 1993 A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14:107.
8. Diepoler HM, Zachoval R, Hoffman RM, Wieranga EA, Santantnio T, Jung MC, et al.: 1995 Possible mechanisms involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006.
9. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Guiberti T, et al.: 1990 Cellular immune response to hepatitis B virus-encoded antigens in acute, chronic hepatitis B infection Cellular immune response to hepatitis B virus-encoded antigens in acute, chronic hepatitis B infection. J Immunol 145:3442.
10. Chisari FV, Ferrari C: 1995 Hepatitis B virus immunopathogenesis. Ann Rev Immunol 13:29.
11. Yasukawa MA, Inatsuki A, Horiuchi T, Kobayashi Y: 1991 Functional heterogeneity among herpes simplex virus-specific human CD4+ T cells. J Immunol 146:1341.
12. Schmid DS: 1988 The human MHC-resrticted cellular response to herpes simplex type 1 is mediated by CD4+, CD8-T cells, is restricted to the DR region of the MHC complex. J Immunol 140:3610.
13. Cease KB, Berzofsky JA: 1994 Toward a vaccine for AIDS: The emergence of immunobiology-based vaccine development. Ann Rev Immunol 12:923.
14. Hahn S, Gehri R, Erb P: 1995 Mechanism, biological significance of CD4 mediated cytotoxicity. Immunol Rev 146:57.
15. Modlin RL: 1994 Th1-Th2 paradigm: insights from leprosy. J Invest Derm 102(6):828.
16. Erb P, Grogg D, Troxler M, Kennedy M, Fluri M: 1990 CD4+ T cell mediated killing of MHC class II-positive antigen-presenting cells I Characterization of target cell recognition by in vivo, in vitro activated CD4+ killer T cells. J Immunol 144:790.
17. Ozdemirli M, Elkhatib M, Bastiani L, Akdeniz H, Kuchroo V, Ju ST: 1992 The cytotoxic process of CD4 Th1 clones. Cell Immunol 149:1889.
18. Yamamura MK, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL: 1991 Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277.
19. Kaufmann SHE: 1993 Immunity to intracellular bacteria. Ann Rev Immunol 11:129.
20. Romagnani S: 1994 Lymphokine production by human T cells in disease states. Ann Rev Immunol 12:227.
21. Reina L, Salone-Marussig M, Grillot D, Corradin G, Millgen F, Del Giudice, G, et al.: 1991 In vitro activity of CD4+, CD8+ T lymphocytes from mice immunized with a malaria synthetic peptide. Proc Natl Acad Sci 88:7963.
22. Romani L, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Puccetti P, Bistoni F: 1993 CD4+ subset expression in murine candidiasis: Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol 150:925.
23. Wang R, Charoenvit Y, Corradin G, De La Vega P, Franke E, Hoffman SL: 1996 Protection against Plasmodium yoelii Sporozoite Surface Protein 2 linear peptide induction of CD4+ T cell, IFN-gamma-dependent elimination of infected hepatocytes. J Immunol 157:4061.
24. Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Appella E: 1992 Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256:1817.
25. Chicz, RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL: 1993 Specificity, promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27.
26. Rudensky AY, Preston-Hurlburt P, Hong, S-C, Barlow A, Janeway CA: 1991 Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622.
27. Chicz, RM, Urban RG, Lane WS, Gorga JC, Stern, LJ, Vignali, DAA, Strominger, JL: 1992 Predominant naturally processed peptides bound to HLA DR1 are derived from MHC-related molecules, are heterogeneous in size. Nature 358:764.
28. Nelson, CA, Roof, RW, McCourt, DW, Unanue, ER: 1992 Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule 1-Ak. Proc Natl Acad Sci 89:7380.
29. Germain, RN, Marguiles, DH: 1993 The biochemistry, cell biology of antigen processing, presentation. Ann Rev Immunol 11:403.
30. Germain, RN: Antigen processing, presentation, in: Paul WE (eds.): Fundamental Immunology, Raven, New York, 1993, 629.
31. Brown, JH, Jardetzky, TS, Gorga, J, Stern, JC, Urban, RG, Strominger, JL, Wiley, DC: 1993 Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33.
32. Stern, LJ, Brown, JH, Jardetzky, TS, Gorga, JC, Urban, RG, Strominger, JL, Wiley, DC: 1994 Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215.
33. Madden, DR: 1995 The three-dimensional structure of peptide-MHC complexes. Ann Rev Immunol 13:587.
34. Fremont, DH, Hendrickson, WA, Marrack, P, Kappler, J: 1996 Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001.
35. Rothbard, JB, Lechler, RI, Howland, K, Bal, D, Eckels, DD, Sekaly, R, Long, EO, Taylor, WR, Lamb, JR: 1988 Structural model of HLA-DR1 restricted T cell antigen recognition. Cell 52:515.
36. Krieger, JI, Karr, RW, Grey, HM, Yu, W-Y, O'Sullivan, D, Batovsky, L, Zheng, Z-L, Colon, SM, Gaeta, FCA, Sidney, J, Albertson, M, del Guercio, M-F, Chesnut, RW, Sette, A: 1991 Single amino acid changes in DR, antigen define residues critical for peptide-binding, T cell recognition. J Immunol 146:2331.
37. Jardetzky, TS, Gorga, JC, Busch, R, Rothbard, J, Strominger, JL, Wiley, DC: 1990 Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO 9:1797.
38. Sette, A, Buus, S, Appella, E, Smith, JA, Chesnut, RW, Miles, C, Solon, SM, Grey, HM: 1989 Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci 86:3296.
39. Rothbard, JB, Taylor, WR: 1988 A sequence pattern common to T cell epitopes. EMBO 7:93.
40. Hammer, J, Valsasnini, P, Tolba, K, Bolin, D, Higelin, J, Takacs, B, Sinigaglia, F: 1993 Promiscuous, allele-specific anchors in HLA-DR binding peptides. Cell 74:197.
41. Hammer, J, Belunis, C, Bolin, D, Papadopoulos, J, Walsky, R, Higelin, J, Danho, W, Sinigaglia, F, Nagy, Z: 1994 High-affinity binding of short peptides to major histocompatability complex class II molecules by anchor combinations. Proc Natl Acad Sci 91:4456.
42. Hammer, J, Bono, E, Gallazi, F, Beunis, C, Nagy, Z, Sinigaglia, F: 1994 Precise prediction of major histocompatibility complex class 11-peptide interaction based on peptide side chain scanning. J Exp Med 180:2353.
43. Sette, A, Sidney, J, Oseroff, C, del Guercio, M-F, Southwood, S, Arrhenius, T, Powell, M, Colon, S, Gaeta, F, Grey, HM: 1993 HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy, specificity in peptide-DR interactions. J Immunol 151:3163.
44. Marshall, K, Wilson, KJ, Liang, J, Woods, A, Zaller, D, Rothbard, JB: 1995 Prediction of peptide affinity to HLA DRB1*0401. J Immunol 154:5927.
45. Sidney, J, Oseroff, C, Southwood, S, Wall, M, Karr, RW, Ishioka, G, Koning, F, Sette, A: 1992 Prediction of peptide affinity to HLA DRB1*0401. J Immunol 149:2643.
46. O'Sullivan, DT, Arrhenius, T, Sidney, J, del Guercio, M-F, Albertson, M, Wall, M, Southwood, S, Colon, SM, Gaeta, F, Sette, A: 1991 On the interaction of promiscuous antigenic peptides with different DR alleles: identification of common structural motifs. J Immunol 147:2663.
47. Hill, CM, Liu, A, Marshall, KW, Mayer, J, Jorgensen, B, Yuan, B, Cubbon, RM, Nichols, EA, Wicker, LS, Rothbard, JB: 1994 Exploration of requirements for peptide binding to HLA DRB1*0101, DRB1*0401. J Immunol 152:2890.
48. Hill, CM, Hayball, JD, Allison, AA, Rothbard, JB: 1991 Conformational, structural characteristics of peptide binding to HLA-DR molecules. J Immunol 47:189.
49. Davenport, MP, Quin, CL, Chicz, RM, Green, BN, Willis, AC, Lane, WS, Bell, JI, Hill, AVS: 1995 Naturally processed peptides from two disease-resistance associated HLA-DR13 alleles show related sequence motifs, the effects of the dimorphism at position 86 of the HLA-DRß chain. Proc Natl Acad Sci 92:6567.
50. Davenport, MP, Ho Shon, IAP, Hill, AVS: 1995 An empirical method for the prediction of T cell epitopes. Immunogenetics 42:392.
51. d molecules in the activation of MHC class II-restricted T cells. J Immunol 147:198.
52. Falk, K, Rotzschke, O, Stevanovic, S, Jung, G, Rammensee, H-G: 1994 Pool sequencing of natural HLA-DR, DQ, DP ligands reveals detailed peptide motifs, constraints of processing, general rules. Immunogenetics 39:230.
53. Doolan, D, Saul, A, Good, M: 1997 Geographically restricted heterogeneity of the Plusmodium falciparum Circumsporozoite Protein: relevance for vaccine development. Infection, Immunity 60:675.
54. Hoffman, SL, Franke, E, Hollingdale, M, Druilhe, P: Attacking the infected hepatocyte, in: Hoffman, SL (ed.): Malaria Vaccine Development: A Multi-Immune Response Approach, American Society for Microbiology, Washington, DC, 1996, 35.
55. Melief, CJM, Offringa, R, Toes, REM, Kast, WM: 1996 Peptide-based cancer vaccines. Curr Opin Immunol 8:651.
56. Robbins, P, Kawakami, Y: 1996 Human tumor antigens recognized by T cells. Curr Opin Immunol 8:628.
57. Chesnut, RW, Sette, A, Celis, E, Wentworth, P, Kubo, RT, Alexander, J, Ishioka, G, Vitiello, A, Grey, HM: Design, testing of peptide based cytotoxic T-cell mediated immunotherapeutics to treat infectious diseases, cancer, in: (Powell, MF, Newman, MJ (eds.): Vaccine Design: The Subunit, Adjuvant Approach, Plenum Press, New York, 1995, 847.
58. Melief, CJ, Kast, WM: 1993 Potential immunogenicity of oncogene, tumor suppressor end products. Curr Opin Immunol 5:709.
59. Miller, LH, Roberts, T, Shahabuddin, M, McCutchan, T: 1993 Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Moland Biochem Parasitology 59:1.
60. Houghton, M, Weiner, A, Han, J, Kuo, G, Choo, Q-L: 1991 Molecular biology of the hepatitis C viruses: implications for diagnosis, development, control of viral disease. Hepatol 14:381.
61. Dusheiko, G, Simmonds, P: 1994 Sequence variability of hepatitis C virus, its clinical relevance. J Viral Hepatol 1:3.
62. Howard, CR, Allison, LM: 1995 Hepatitis B surface antigen variation, protective immunity. Intervirology 38:35.
63. Magnius, LO, Norder, H: 1995 Subtypes, genotypes, molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 38:24.
64. Simmonds, P: 1995 Variability of hepatitis C virus. Hepatol 21:570.
65. Sillier-Moiseiwitsch, F, Margolin, BH, Swanstrom, R: 1994 Genetic-variability of the human immunodeficiency virus: statistical, biological issues. Annu Rev Genet 28:559.
66. Nardin, EH, Nussenzweig, RS: 1993 T cell responses to pre-erythrocytic stages of malaria: role in protection, vaccine development against pre-erythrocytic stages. Annu Rev Immunol 11:687.
67. van der Most, RG, Sette, A, Oseroff, C, Alexander, J, Lau, LL, Southwood, S, Sidney, J, Chesnut, RW, Matoubian, M, Ahmed, R: 1996 Analysis of cytotoxic T cell responses to dominant, subdominant epitopes during acute, chronic lymphocytic choriomeningitis virus infection. J Immunol 157:5543.
68. van der Most, RG, Conception, RJ, Oseroff, C, Alexander, J, Southwood, S, Sidney, J, Chesnut, RW, Ahmed, R, Sette, A: 1997 Uncovering subdominant cytotoxic T-lymphocyte choriomeningitis virus infected BALB/c mice. J Clin Invest, in press.
69. Vitiello, A, Yuan, L, Chesnut, RW, Sidney, J, Southwood, S, Harness, P, Jackson, MR, Peterson, PA, Sette, A: 1996 Immunodominance analysis of CTL responses to the Influenza PR8 virus reveals two new dominant, subdominant Kb-restricted epitopes. J Immunol 157:5555.
70. Sercarz, E, Lehmann, PV, Ametani, A, Benichou, G, Miller, A, Moudgil, K: 1993 Dominance, crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729.
71. Cibotti, R, Kanellopoulos, JM, Cabaniols, J-P, Halle-Panenko, O, Kosmatopoulos, K, Sercarz, E, Lourilsky, P: 1992 Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 89:416.
72. Celis, E, Sette, A, Grey, HM: 1995 Epitope selection, development of peptide based vaccines to treat cancer. Sem Cancer Biol 6:329.
73. Tsai, V, Southwood, S, Sidney, J, Sakaguchi, K, Kawakami, Y, Appella, E, Sette, A, Celis, E: 1997 Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158:1796.
74. Moudgil, K, Sercarz, E: 1994 Can antitumor immune responses discriminate between self, nonself? Immunol Today 15:353.
75. Kawakami, Y, Rosenberg, S: 1997 Immunobiology of human melanoma antigens MART-1, gp100, their use for immuno-gene therapy. Int Rev Immuno 1997;14:173-190.
76. Kawakami, Y, Rosenberg, S: 1997 T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1997;16:313-331
77. Kawakami, Y, Eliyahu, S, Jennings, C, Sakaguchi, K, Kang, X, Southwood, mS, Robbins, PF, Sette, A, Appella, E, Rosenberg, SA: 1995 Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltration T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961.
78. Pfeiffer, C, Murray, J, Madri, J, Bottomly, K: 1991 Selective activation of Th1, Th2 like cells in vivo Response to human collagen IV. Immunol Rev 123:65.
79. Chatruvedi, P, Yu, Q, Southwood, S, Sette, A, Singh, B: 1996 Peptide analogs with different affinities for MHC alter the cytokine profile of T helper cells. Int Immunol 8:745.
80. Alexander, J, Sidney, J, Southwood, S, Maewal, S, Ruppert, J, Oseroff, C, Kubo, RT, Sette, A, Grey, HM: 1994 Development of high potency universal DR-restricted helper epitopes by rational engineering of high affinity DR blocking peptides. Immunity 1:751.
81. Parkhurst, MR, Salgaller, M, Southwood, S, Robbins, PF, Sette, A, Rosenberg, SA, Kawakami, Y: 1996 Efficient induction of melanmoa reactive CTL with peptides modified at HLA-A *0201 binding residues from the melanoma antigen, gp100. J Immunol 157:2539.
82. Topalian, SL, Gonzales, MI, Parkhurst, M, Li, YF, Southwood, S, Sette, A, Rosenberg, SA, Robbins, PF: 1996 Melanomaspecific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 186:1965.
83. Boehncke, W-H, Takeshita, T, Pendleton, CD, Houghten, RA, Sadegh-Nasseri, S, Racioppi, L, Berzofsky, JA, Germain, RN: 1993 The importance of dominant negative effects of amino acid side chain substitution in peptid-MHC molecule interactions, T cell recognition. J Immunol 150:331.
84. Demotz, S, Lanzavecchia, A, Eisel, U, Niemann, H, Wildmann, C, Corradin, G: 1989 Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 142:394.
85. Panina-Bordignon, P, Tan, A, Termijtelen, A, Demotz, S, Corradin, G, Lanzavecchia, A: 1989 Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II, promiscuous recognition by T cells. Eur J Immunol 19:2237.
86. Vitiello, A, Ishioka, G, Grey, HM, Rose, R, Farness, P, LaFond, R, Yuan, L, Chisari, FV, Furze, J, Bartholomeuz, R, Chesnut, RW: 1995 Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: I Induction of a primary CTL response in man. J Clin Invest 95:341.
87. Perkus, ME, Paoletti, E: Recombinant virus as vaccination carrier of heterologous antigens, in: (Kaufmann, SHE (ed.): Concepts in Vaccine Development, Walter de Gruyter, Co, Berlin, 1996, 379.
88. Chakrabarti, S, Robert-Guroff, M, Wong-Staal, F, Gallo, RC, Moss, B: 1986 Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature 320:535.
89. Hu, SL, Kosowski, SG, Dalrymple, JM: 1986 Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 320:537.
90. Kieny, M-P, Tautmann, G, Schmitt, D, Dott, K, Wain-Hobson, S, Alizon, M, Girard, M, Chamaret, S, Laurent, A, Montagnier, L, Lecocq, JP: 1986 AIDS virus env protein expressed from a recombinant vaccinia virus. Bio/Technology 4:790.
91. Top, FH, Grossman, RA, Bartelloni, PJ, Segal, HE, Dudding, BA, Russell, PK, Buescher, EL: 1971 Immunization with live types 7, 4 adenovirus vaccines 1 Safety, infectivily, antigenicity, potency of adenovirus type 7 vaccine in humans. J Infect Dis 124:148.
92. Chanda, PK, Natuk, RJ, Mason, BB, Bhat, BM, Greenberg, L, Dheer, SK, Molnar-Kimber, KL, Mizutani, S, Lubeck, MD, Davis, AR, Hung, PP: 1990 High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper independent adenovirus type 7 recombinants. Virology 175:535.
93. Kofler, N, Ruedl, C, Klima, J, Recheis, H, Bock, G, Wick, G, Wolf, H: 1996 Preparation, characterization of poly-(D,L-lactide-co-glycolide), poly-(L lactic acid) microspheres with entrapped pneumotropic bacterial antigens. J Immunol Methods 192:25.
94. Eldridge, JH, Stass, JK, Chen, D, Marx, PA, Tice, TR, Gilley, RM: 1993 New advances in vaccine delivery systems. Sem Hematol 30:16.
95. Falo, Jr, LD, Kovacsovics-Bankowski, M, Thompson, K, Rock, KL: 1995 Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Med 7:649.
96. Warren, HS, Vogel, FR, Chedid, LA: 1986 Current status of immunological adjuvants. Annu Rev Immunol 4:369.
97. Gupta, RK, Relyveld, EH, Lindblad, EB, Bizzini, B, Ben-Efraim, S, Gupta, CK: 1993 Adjuvants - a balance between toxicity, adjuvanticity. Vaccine 11:293.
98. Reddy, R, Zhou, R, Nair, S, Huang, L, Rouse, BT: 1992 In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 148: 1585.
99. Rock, KL: 1996 A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131.
100. Ulmer, JB, Donnelly, JJ, Parker, SE, Rhodes, GH, Feigner, PI, Dwarki, VJ, Gromkowski, SH, Deck, RR, DeWitt, CM, Friedman, A, Hawe, LA, Leander, KR, Martinez, D, Perry, HC, Shiver, JW, Montgomery, DL, Liu, MA: 1993 Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745.
101. Robinson, HL, Hunt, LA, Webster, RG: 1993 Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11:957.
102. Shiver, JW, Ulmer, JB, Donnelly, JJ, Liu, MA: Naked DNA vaccination, in: Kaufmann SHE (ed.): Concepts in Vaccine Development, Walter de Gruyter, Co, Berlin, 1996, 379.
103. Gambier, J, Pleiman, C, Clark, M,: 1994 Signal transduction by the B cell antigen receptor, its coreceptors. Ann Rev Immunol 12:457-486.
104. Clark, E, Lane, P: 1991 Regulation of human B-cell activation, adhesion. Ann Rev Immunol.
105. Del Guercio, M F, Alexander, J, Kubo, R T, Arrhenius, T, Maewal, A, Appella, E, Hoffman, S L, Jones, T, Valmori, D, Sakaguchi, K, Grey, H M, Sette, A: 1997 Potent immunogenic short linear peptide constructs composed of B cell epitopes, Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo. Vaccine 15(4):441-448.
106. Mellouk, S, Berviguier, P, Druilhe, P, Sedegah, M, Galey, B, Yuan, L, Leef, M, Charoenvit, Y, Paul, C, Hoffman, S L, Beaudoin, R: 1990 Evaluation of an in vitro aimed at measuring protective antibodies against sporozoites. Bull World Health Organ 68(suppl): 52-59.
107. Wang, R, Charoenvit, Y, Corradin, G, Porrozzi, R, Hunter, R L, Glenn, G, Alving, C R, Church, P, Hoffman, S L: 1995 Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelli circumsporozoite protein multiple antigen peptide vaccine. J Immunol 154:2784-2793.
108. Valmori, D, Pessi, A, Bianchi, E, Corradin, G: 1992 Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. Immunol Methods 149:717-721.
109. World Health Organization report: 1996 State of the world's vaccines, immunization.
110. Jordan Annual Report: 1996 Accelerated development of vaccines.
111. Milich, DR, Chisari, FV: 1982 Genetic regulation of the immune response to hepatitis B surface antigen (HbsAg) I H-2 restriction. J Immunol 129:320-325.
112. Milich, D R, Leroux-Roels, G G, Louie, RE, Chisari, F V: 1984 Genetic regulation of the immune response to hepatitis B surface antigen (HbsAg) IV Distinct H-2-linked genes control antibody responses to different HbsAg determinants on the same molecule, map to the I-A, I-C subregions. J Exp Med 159:41-56.
113. Milich, D R: 1988 T-, B-cell recognition of hepatitis B viral antigens. Immunol Today 9:380-386.
114. Alper, C A, Kruskall, M S, Marcus-Bagley D, Craven D E, Katz, A J, Brink, S J, Dienstag, JL, Awdeh, Z, Yunis E J: 1989 Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321:708-712.
115. Egea, E, Iglesias, A, Salazar, M, Morimoto, C, Kruskall, M S, Awdeh, Z, Schlossman, S F, Alper, C A, Yunis, E J,: 1991 The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 173:531-538.
116. Song, H, Price, PW, Cerny, J: 1997 Age-related changes in antibody repertoire: contribution from T cells. Immunolog Rev 160:55-62.
117. Wenger, JD, Booy, R, Heath, PT, Moxon, R: 1997 Epidermiological impact of conjugate vaccines on invasive disease caused by haemophilus influenzae type b In: New Generation Vaccines, Second Edition, Revised, Expanded Eds Levine, MM, Woodrow, GC, Kaper, JB, Cobon, GS, pp 489, Marcel Dekker, Inc, New York.
118. Robbins, J, Schneerson, R, Szu, S O-specific polysaccharide-protein conjugates for prevention of enteric bacterial diseases.
119. World Health Organization Expert Committee on Biologic Standardization: 1993 Requirements on Vi polysaccharide for typhoid. Technical Report Series 840 14-32.
120. Kasper, D, Paoletti, L, Wessels, M, Guttormsen, H-K, Carey, V, Jennings, H, Baker, C,: 1996 Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 98:2308-2314.
121. Guidotti, L G, o, K, Hobbs, M V, Ishikawa, T, Runkel, L, Schreiber, R D, Chisari, F V: 1994 Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. PNAS 91:3764-3768.
122. Guidotti, L G, Ishikawa, T, Hobbs, M V, Matzke, B, Schreiber, R, Chisari, FV: 1996 Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36.
123. Livingston, B, Claire, C, Grey, H, Ishioka, G, Chisari, F V, Fikes, J, Grey, H, Chesnut, R W, Sette, A: 1997 The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 159:1383-1392.
124. Livingston, BD, Alexander, J, Crimi, C, Oseroff, C, Vadi, R, Celis, E, Daly, K, Guidotti, LG, Chisari, FV, Fikes, J, Chesnut, RW, Sette, A Altered helper T lymphocyte (HTL) function associated with chronic HBV infection, its role in response to therapeutic vaccination in humans. 1998, in press.
125. + T cell responses associated with control of viremia. Science 278(5342): 1447-1450.
126. Walter, E, Greenberg, P, Gilbert, M, Goodrich, J, Watanabe, K, Thoas, E, Riddell, S: 1995 Reconstitution of cellular immunity against cytomegalovirus in recipients of allogenic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044.
127. Hu, J, Kindsvogel, W, Busby, S, Bailey, M, Shi, Y, Greenberg, P: 1993 An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med 177:1681-1690.
128. Bodmer, JG, Marsh, SGE, Albert, ED, Bodmer, WF, Bontrop, RE, Charron, D, Dupont, B, Erlich, HA, Mach, B, Mary, WR, Parham, P, Sasazuki, T, Schreuder, GMT, Strominger, JL, Svejgaard, A, Terasaki, PI: 1995 Nomenclature for factors of the HLA system. Hum Immunol 43:149.
129. Parham, P, Adams, EJ, Arnett, KL: 1995 The origins of HLA-A, B, C polymorphism. Immunol Rev 143:141.
130. Sidney, J, Grey, HM, Southwood, S, Celis, E, Wentworth, PA, del Guercio, M-F, Kubo, RT, Chesnut, RW, Sette, A: 1996 Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide binding repertoires of common HLA molecules. Hum Immunol 45:79.
131. Sidney, J, Grey, HM, Kubo, RT, Sette, A: 1996 Practical, biochemical, evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17:261.
132. Sidney, J, Kubo, RT, Wentworth, PA, Alexander, J, Chesnut, RW, Grey, HM, Sette, A: Broadly reactive HLA restricted T cell epitopes, their implications for vaccine design, in: Kaufmann SHE (ed.): Concepts in Vaccine Development, Walter de Gruyter, Berlin, 1996, 169.
133. Sidney, J, del Guercio, M-F, Southwood, S, Engelhard, VH, Appella, E, Grey, HM, Sette, A: 1995 Several HLA alleles share overlapping peptide specificities. J Immunol 154:247.
134. del Guercio, M-F, Sidney, J, Hermanson, G, Perez, C, Grey, HM, Kubo, RT, Sette, A: 1995 Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685.
135. Sidney, J, Southwood, S, del Guercio, M-F, Grey, HM, Chesnut, RW, Kubo, RT, Sette, A: 1996 Specificity, degeneracy in peptide binding to HLA-B7-like class 1 molecules. J Immunol 157:3480.
136. Threlkeld, SC, Wentworth, PA, Kalams, SA, Wilkes, B M, Ruhle, D J, Sidney, J, Southwood, S, Walker, B D, Sette, A Degenerate, promiscuous recognition by CTL ofpeptides presented by the MHC class I A3-like superfamily. J Immunol 159(4):1648-1657, 1997.
137. Doolan, D L, Hoffman, S L, Southwood, S, Wentworth, P A, Sidney, J, Chesnut, R W, Keogh, E, Appella, E, Nahlen, B L, Hawley, W A, Nutman, T B, Gordon, D M, Udkhayakumar, V, Lal, A A, Sette, A Degenerate cytotoxic T cell epitopes from P falciparum restricted by multiple HLA-A, HLA-B supertype alleles. Immunity 7(1):97-112, 1997.
138. Bertoni, R, Sidney, J, Fowler, P, Chisari, F, Sette, A Human histocompatibility leukocyte antigen-binding supermotils predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 100(3):503-513, 1997.
139. Sinigaglia, F, Guttinger, M, Kilgus, J, Doran, DM, Matile, H, Etlinger, H, Trzeciak, A, Gillessen, D, Pink, JRL: 1988 A malaria T-cell epitope recognized in association with most mouse, human MHC class II molecules. Nature 336:778.
140. Ferrari, C, Bertoletti, A, Penna, A, Cavilli, A, Valli, A, Missale, G, Pilli, M, Fowler, P, Giuberti, T, Chisari, FV, Fiaccadori, F: 1991 Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88:214.
141. Busch, R, Strang, G, Howland, K, Rothbard, JB: 1990 Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol 2:443.
142. Roche, PA, Cresswell, P: 1991 High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J Immunol 144:1849.
143. Sette, A, Southwood, S, Miller, J, Appella, E: 1995 Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 181:677.
144. Makherek, G, Gnau, V, Jung, G, Rammensee, H-G, Melms, A: 1995 Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J Exp Med 181:527.
145. Southwood, S, Sidney, J, Kondo, A, del Guecio, M-F, Appella, E, Hoffman, S, Kubo, R T, Chesnut, R W, Grey, H M, Sette, A: 1998 Several common HLA-DR types share a largely overlapping peptide binding repertoire. J Immunol 160(7):3363-3373.